
New Data on the Subcutaneous Long-Acting Injectable Antipsychotic Formulation of Risperidone
Check out these exciting updates from the recent RISE study on TV-46000, a subcutaneous long-acting injectable antipsychotic formulation of risperidone.
"Schizophrenia doesn't stop at any door..."
Christoph U. Correll, MD, shared exciting updates from the recent
Patients who completed RISE without relapse or who were newly recruited were eligible for the subsequent SHINE study. Significantly, 54% of study participants were African American, addressing the issue of minority population underrepresentation in clinical trials.
Correll shared he is also excited about the upcoming treatment from Teva Pharmaceuticals,
Dr Correll is professor at the Institute of Behavioral Science, Feinstein Institutes for Medical Research; medical director of the Recognition and Prevention Program in the Department of Psychiatry at Zucker Hillside Hospital; and professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.